Tragara Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 41
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: T20505258EFEN
Leaflet:

Download PDF Leaflet

Tragara Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Tragara Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Tragara Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Tragara Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Tragara Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Tragara Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Tragara Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Tragara Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Tragara Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Tragara Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Tragara Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Tragara Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Tragara Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Tragara Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Pipeline Products Glance
Tragara Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Tragara Pharmaceuticals, Inc. – Drug Profiles
Apricoxib + Erlotinib
  Product Description
  Mechanism of Action
  R&D Progress
Apricoxib + Lapatinib + Capecitabine
  Product Description
  Mechanism of Action
  R&D Progress
Capoxigem
  Product Description
  Mechanism of Action
  R&D Progress
Capoxigem + Docetaxel/Pemetrexed
  Product Description
  Mechanism of Action
  R&D Progress
Capoxigem + Gemcitabine + Erlotinib
  Product Description
  Mechanism of Action
  R&D Progress
Kymena
  Product Description
  Mechanism of Action
  R&D Progress
SB1317
  Product Description
  Mechanism of Action
  R&D Progress
Tragara Pharmaceuticals, Inc. – Pipeline Analysis
Tragara Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Tragara Pharmaceuticals, Inc. Pipeline Products By Target
Tragara Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Tragara Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates
Tragara Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 22, 2010: S*BIO's SB1317 Enters Phase I Clinical Trial In Hematologic Malignancies
Sep 09, 2010: Tragara Initiates Phase I Clinical Program For TG02 For Treatment Of Hematologic Malignancies
Apr 07, 2010: Patient Enrollment Complete In Tragara Pharmaceuticals' Phase II Trial Of Capoxigem In Non-Small Cell Lung Cancer
Apr 06, 2010: Tragara Completes Patient Enrollment In Phase II Trial Of Capoxigem In NSCLC
Apr 14, 2009: Apricoxib Phase I Study Results To Be Presented At AACR In Denver
Nov 28, 2007: S*BIO Pte Ltd Expands Pipeline With The Development Of A Unique Flt3 -CDK Inhibitor As A Targeted Therapy For Acute Leukemias
Financial Deals Landscape
Tragara Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Tragara Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Tragara Pharmaceuticals Secures $5 Million In Series B Financing
Tragara Pharmaceuticals Secures $40 Million In Series A Financing
Licensing Agreements
S*BIO Enters Into Licensing Agreement With Tragara Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Tragara Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Tragara Pharmaceuticals, Inc. - Phase II, 2010
Tragara Pharmaceuticals, Inc. - Phase I, 2010
Tragara Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2010
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010
Tragara Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2010
Tragara Pharmaceuticals, Inc. – Recent Pipeline Updates, 2010
Tragara Pharmaceuticals, Inc., Deals Summary, 2004 to 2010 34

LIST OF FIGURES

Tragara Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Tragara Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Tragara Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Tragara Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Tragara Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
Tragara Pharmaceuticals, Inc. - Pipeline By Target, 2010
Tragara Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010 26

Ask Your Question

Tragara Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: